Influenza;Influenza

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 36, Issue 2, 2003, Pages 267-274

  Forleo Neto, Eduardo ^a   Halker, Elisa ^a   Santos, Verônica Jorge ^a   Paiva, Terezinha Maria ^b   Toniolo Neto, João ^c  

^a Projeto VigiGripe   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Epidemiology; Flu; Influenza; Treatment; Vaccine

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ARTICLE; BRAZIL; BRONCHITIS; CLINICAL FEATURE; COUGHING; DIARRHEA; DRUG EFFICACY; EAR INFECTION; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFLUENZA VIRUS C; MUTAGENESIS; NAUSEA; NOSE DISEASE; NOSE INFECTION; PHARYNGITIS; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINUSITIS; VIRUS STRAIN; VOMITING;

INFLUENZA VIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INSERTION SEQUENCES;

EID: 0038198886     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822003000200011     Document Type: Article

References (52)

1. Ambrosch F, Fedson D. Epidemiology of influenza vaccine distribution. In: Abstract, Options for the control of influenza IV) p126, 2000.
2. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza, NY: Alan R. Liss, Inc., New York, p.155-168, 1986.
3. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. The Journal of Pediatrics 136: 168-175, 2000.
4. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. The Journal of Infectious Diseases 181: 1133-1137, 2000.
5. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, lacuzio D, Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. The New England Journal of Medicine 338: 1405-1412, 1998.
6. Beyer WEP, Palache AM, Osterhaus ADME. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literature. Clinical Drug Investigation 15: 1-12, 1998.
7. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. The Journal of Infectious Diseases 136: S652-S655, 1977.
8. Calfee DP, Hayden FG. New approaches to influenza chemoterapy-Neuraminidase inhibitors. Drugs 56: 537-553, 1998.
9. Campbell DS and Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. Journal of Occupational and Environmental Medicine 39: 408-414, 1997.
10. Centers for Disease Control. Neuraminidase inhibitors for treatment of influenza A and B infections. Morbidity and Mortality Weekly Report 48 (RR-14): 1-10, 1999.
11. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 50 (RR-4): 1-44, 2001.
12. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Archives of Pediatrics & Adolescent Medicine 149: 1113-1117, 1995.
13. Cox NJ, Fukuda K. Influenza. Infectious Disease Clinics of North America 12: 27-38, 1998.
14. Cox NJ, Subbarao K. Influenza. Lancet 354: 1277-1282, 1999.
15. Dab W, Quenel P, Cohen JM, Hannoun C. A new influenza surveillance system in France: the Ile-de-France "GROG". 2. Validity of indicators (1984-1989). European Journal of Epidemiology 7: 579-587, 1991.
16. Ghendon Y. Influenza its impact and control. World Health Statistic 1992; Q 45: 306-311. Quoted in: Lüscher-Mattli, M. Influenza chemotherapy: A review of the present state of art and of new drugs in development. Archives of Virology 145: 2233-2248, 2000.
17. Ghendon Y. Influenza its impact and control. World Health Statistic 1992; Q 45: 306-311. Quoted in: Lüscher-Mattli, M. Influenza chemotherapy: A review of the present state of art and of new drugs in development. Archives of Virology 145: 2233-2248, 2000.
18. Govaert ME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. British Medical Journal 307: 988-990, 1993.
19. Grupo Regional de Observação da Gripe. Boletim GROG (Grupo Regional de Observação da Gripe) 3: 1-6, 1998.
20. Hannoun C, Dab W, Cohen JM. A new influenza surveillance system in France: the Ile-de-France "GROG". 1. Principles and methodology. European Journal of Epidemiology 5:285-293, 1989.
21. Hannoun C. Role of international networks for the surveillance of influenza. European Journal of Epidemiology 10: 459-461, 1994.
22. Hannoun C. La grippe et ses virus. Paris, France: Presses Universitaires de France, p.60-61, 1995.
23. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K. Efficacy and safety of the neuraminidase. The New England Journal of Medicine 337: 874-880, 1997.
24. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. American Journal of Diseases of Children 145: 445-448, 1991.
25. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H. Fukuda K. Influenza and the rates of hospitalization for respiratory disease among infants and young children. The New England Journal of Medicine 342: 232-139, 2000.
26. Jennings R, Smith TL, Spencer RC, Mellersh AM, Edey D, Fenton P, Potter CW. Inactivated influenza virus vaccine in man: a comparative study of subunit and split vaccines using two methods for assessment of antibody responses. Vaccine 2: 75-80, 1984.
27. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT The Guillian-Barré Syndrome and the 1992-1993 and 1993-1994 influenza vaccines. The New England Journal of Medicine 339: 1797-1802, 1998.
28. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Scientific American 280: 78-87, 1999.
29. Lui KJ, Kendal AR Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. American Journal of Public Health 77: 712-716, 1987.
30. McIntosh K, Lieu T. Is it time to give influenza vaccine to healthy infants? The New England Journal of Medicine 342: 275-276, 2000.
31. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Annals of Internal Medicine 121: 947-952, 1994.
32. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. New England Journal of Medicine 342: 225-231, 2000.
33. Nichol KL. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults. A randomized controlled trial. The Journal of the American Medical Association 282: 137-144, 1999.
34. Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebocontrolled trial. Archives of Internal Medicine 156: 1546-1550, 1996.
35. Nichol KL, Wuorenma J, Von Sternberg T Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Archives of Internal Medicine 158: 1769-1776, 1998.
36. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ (eds) Textbook of influenza. Oxford, UK: Blackwell Science, Oxford, UK, p. 219-264, 1998.
37. Noble GR. Epidemiologic and clinical aspects of influenza. In: Beare AS (ed) Basic and applied influenza research. CRC Press, Boca Raton, Florida: 11-50, 1982.
38. Organização Mundial da Saúde. Recommendation for the composition of influenza vírus vaccines for 1999. Weekly Epidemiological Record 73: 305-308, 1998.
39. Organiza̧ão Mundial da Saúde. Weekly Epidemiological Record 75: 281-288, 2000.
40. Organização Mundial da Saúde. Weekly Epidemiological Record 75: 330-333, 2000.
41. Organização Mundial da Saúde. Weekly Epidemiological Record 76: 58-61, 2001.
42. Oxford JS, Lambkin R. Targeting influenza virus neuraminidase - a new strategy for antiviral therapy. Drug Discovery Today 3: 448-456, 1998.
43. Palache AM. Influenza vaccines: a reappraisal of their use. Drugs 54: 841-856, 1997.
44. Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger LB. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. The Journal of the American Medical Association 253: 1136-1139, 1985.
45. Projeto VigiGripe. Boletim Notícias VigiGripe 2: 2-5, 2001.
46. Ropper AH, Victor M. Influenza vaccination and the Guillian-Barré Syndrome. New England Journal of Medicine 339:1845-1846, 1998.
47. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. American Journal of Public Health 87: 1944-1950, 1997.
48. Spila-Alegiani S, Salmaso S, Rota MC, Tozzi AE, Raschetti R. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine 17: 1898-1904, 1999.
49. Toniolo-Neto J. "Dia de Vacinaçao do Idoso" e "Projeto VigiGripe": Conjunto de medidas interativas para a prevenção da influenza e suas complicações. Tese de Doutorado, Universidade Federal de São Paulo, Programa de Pós-graduação em Medicina Interna e Terapêutica. Sao Paulo, Escola Paulista de Medicina, 2001.
50. Treanor JJ, Hayden FG, Vrooman PS, Bárbaras R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. The Journal of the American Medical Association 283: 1016-1024, 2000.
51. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA: The Journal of the American Medical Association 281: 908-913, 1999.
52. Zei T, Neri M, Lorio AM. Immunogenicity of trivalent subunit and split influenza vaccines (1989-90 winter season) in volunteers of different groups of age. Vaccine 9: 613-617, 1991.